Perrigo Company plc (NYSE:PRGO) Receives $19.33 Consensus PT from Brokerages

Shares of Perrigo Company plc (NYSE:PRGO) have been given a consensus rating of “Reduce” by the six brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $19.3333.

PRGO has been the subject of several research analyst reports. Zacks Research cut Perrigo from a “hold” rating to a “strong sell” rating in a report on Friday, March 20th. Argus upgraded Perrigo to a “hold” rating in a report on Wednesday, January 14th. Canaccord Genuity Group dropped their price target on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th.

Perrigo Stock Down 1.2%

Shares of NYSE PRGO opened at $11.68 on Tuesday. The firm’s fifty day moving average is $11.46 and its 200 day moving average is $14.25. Perrigo has a 52 week low of $9.23 and a 52 week high of $28.43. The company has a quick ratio of 1.63, a current ratio of 2.76 and a debt-to-equity ratio of 1.23. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -1.14, a PEG ratio of 1.39 and a beta of 0.47.

Perrigo (NYSE:PRGO) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.03). The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Perrigo had a negative net margin of 33.51% and a positive return on equity of 9.41%. Perrigo’s revenue was down 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.93 EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. On average, equities research analysts expect that Perrigo will post 2.13 earnings per share for the current year.

Perrigo Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 24th. Investors of record on Monday, March 2nd were given a dividend of $0.29 per share. The ex-dividend date was Monday, March 2nd. This represents a $1.16 annualized dividend and a dividend yield of 9.9%. Perrigo’s payout ratio is currently -11.28%.

Institutional Trading of Perrigo

Several institutional investors and hedge funds have recently bought and sold shares of PRGO. Geneos Wealth Management Inc. raised its position in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares in the last quarter. Kestra Investment Management LLC boosted its position in shares of Perrigo by 57.1% during the second quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after purchasing an additional 642 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Perrigo by 89.1% in the third quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock worth $38,000 after purchasing an additional 838 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Perrigo by 116.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after buying an additional 1,014 shares during the period. Finally, UMB Bank n.a. grew its position in shares of Perrigo by 161.5% in the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after buying an additional 1,213 shares during the period. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.